How do enteroviruses almost completely evade the attentions of CD8+ T cells?
肠道病毒是如何几乎完全逃避CD8 T细胞的注意的?
基本信息
- 批准号:8811097
- 负责人:
- 金额:$ 41.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-01 至 2018-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAntibodiesAntigen PresentationAntiviral AgentsAttentionBacteriaCD4 Positive T LymphocytesCD8B1 geneCellsCodeComplexCoxsackie VirusesCross PresentationCross-PrimingDNA VirusesDataDendritic CellsEducational process of instructingEnterovirusEpitopesEukaryotic CellFamilyHealthImmuneImmune systemIn VitroInfectionLinkMHC Class I GenesMemoryMessenger RNAMusPathway interactionsPeptidesPhenotypeProcessProteinsRNA VirusesRouteSurfaceT cell responseT-LymphocyteTestingTranslatingViralViral ProteinsVirusVirus DiseasesWorkcell typeco-infectiondesignextracellularimmunogenicimmunogenicityin vivomouse modelpreventresearch studyuptake
项目摘要
DESCRIPTION (provided by applicant): The immune system mounts strong CD8+ T cell responses to almost all acute virus infections. However, one virus genus - the enteroviruses - is a stark exception. These viruses can replicate to extremely high titers in vivo, and they induce CD4+ T cells and antibodies, yet these viruses almost completely avoid triggering na¿ve CD8+ T cells. Herein, using the CVB3 mouse model, we shall investigate the mechanism(s) by which enteroviruses achieve this remarkable feat. Antiviral CD8+ T cell responses are initiated when na¿ve CD8+ T cells are activated (or "primed") by contact with an MHC class I / epitope peptide complex on the surface of dendritic cells (DCs). Some viruses can infect DCs, in which case their proteins, being synthesized endogenously (i.e., within the DC) will enter the cell's MHC class I pathway, ultimately triggering CD8+ T cells; this process is called direct priming. However, there are at least two situations in which direct priming cannot occur. First, some viruses that infect DCs also encode proteins that very effectively inhibit MHC class I presentation, rendering the infected DC incapable of antigen presentation. Second, many viruses do not infect DCs. Nevertheless, in both of these cases, the host still mounts strong CD8+ T cell responses to most viruses. It is now known that viral proteins that have been released from infected cells can be taken up by a subset of uninfected DCs, allowing immunogenic proteins to be separated from MHC-inhibitory proteins; these DCs can present viral epitopes on MHC class I. This process is called cross-presentation and, if it results in the triggering of naive CD8+ T cells, it is termed cross-priming. This explains how the immune system can mount strong CD8+ T cell responses to almost all acute virus infections. Why can't it do so for CVB3? In Aim 1, I will investigate the possibility that CVB3 specifically inhibits the cross-priming pathway, preventing uninfected host DCs from capturing viral proteins. In addition, I have conceived of another explanation: that immunological information may be transferred not as protein, but as mRNA, and that the unique capacity of enteroviruses to evade CD8+ T cells results from the unusual coding strategy of these viruses. This mRNA transfer idea may be important beyond enteroviruses, because it also can explain the absence of CD8+ T cell responses to extracellular bacteria. Aims 2 & 3 test this new, and potentially-important, hypothesis. Aim 1. To assess the effect of CVB3 infection on cross-presentation / cross-priming. Aim 2. To ask if mRNA coding strategy explains how enteroviruses can almost completely evade naive CD8+ T cells, while most viruses induce strong CD8+ T cell responses. Aim 3. To determine if mRNA regulatory sequences explain why extracellular bacteria fail to induce strong CD8+ T cell responses.
描述(由申请人提供):免疫系统对几乎所有急性病毒感染都会产生强烈的 CD8+ T 细胞反应,然而,一种病毒属——肠道病毒——是一个明显的例外,这些病毒可以在体内复制到极高的滴度。诱导 CD4+ T 细胞和抗体,但这些病毒几乎完全避免触发 na¿在此,我们将使用 CVB3 小鼠模型研究肠道病毒实现这一非凡壮举的机制。 ve CD8+ T 细胞通过与树突状细胞 (DC) 表面的 MHC I 类/表位肽复合物接触而被激活(或“启动”)。一些病毒可以感染 DC,在这种情况下,它们的蛋白质是内源合成的。 ,在DC内)将进入细胞的MHC I类途径,最终触发CD8+T细胞;但是,至少有两种情况是直接启动的。首先,一些感染 DC 的病毒也编码非常有效地抑制 I 类 MHC 呈递的蛋白质,使受感染的 DC 无法呈递抗原。宿主仍然对大多数病毒产生强烈的 CD8+ T 细胞反应,现在已知从受感染细胞释放的病毒蛋白可以被未受感染的 DC 子集吸收,从而使免疫原性蛋白与 MHC 抑制蛋白分离。这些 DC 可以在 I 类 MHC 上呈递病毒表位。这个过程称为交叉呈递,如果它导致初始 CD8+ T 细胞的触发,则称为交叉启动,这解释了免疫系统如何增强。 CD8+ T 细胞对几乎所有急性病毒感染都有反应,为什么 CVB3 不能这样做?在目标 1 中,我将研究 CVB3 特异性抑制交叉启动途径、阻止未感染宿主的可能性。此外,我还想到了另一种解释:免疫信息可能不是以蛋白质的形式,而是以 mRNA 的形式传递,而肠道病毒逃避 CD8+ T 细胞的独特能力源于这些细胞的不寻常的编码策略。这种 mRNA 转移的想法可能比肠道病毒更重要,因为它还可以解释 CD8+ T 细胞对细胞外细菌缺乏反应的原因。评估 CVB3 感染对交叉呈递/交叉引发的影响 目标 2. 询问 mRNA 编码策略是否可以解释肠道病毒如何几乎完全逃避初始 CD8+ T 细胞,而大多数病毒会诱导强烈的 CD8+ T 细胞反应。确定 mRNA 调控序列是否可以解释为什么细胞外细菌无法诱导强烈的 CD8+ T 细胞反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J. Lindsay Whitton其他文献
Targeting plasmid‐encoded proteins to the antigen presentation pathways
将质粒编码的蛋白质靶向抗原呈递途径
- DOI:
10.1111/j.0105-2896.2004.0135.x - 发表时间:
2004-06-01 - 期刊:
- 影响因子:8.7
- 作者:
J. Leifert;M. Rodriguez;F. Rodríguez;J. Lindsay Whitton - 通讯作者:
J. Lindsay Whitton
J. Lindsay Whitton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J. Lindsay Whitton', 18)}}的其他基金
Coxsackieviral pancreatitis: autophagy, proteolysis, and inflammation
柯萨奇病毒性胰腺炎:自噬、蛋白水解和炎症
- 批准号:
9225171 - 财政年份:2015
- 资助金额:
$ 41.47万 - 项目类别:
Analyzing the effects of type I interferons in the enterovirus-infected heart
分析 I 型干扰素对肠道病毒感染心脏的影响
- 批准号:
8997975 - 财政年份:2015
- 资助金额:
$ 41.47万 - 项目类别:
Analyzing the effects of type I interferons in the enterovirus-infected heart
分析 I 型干扰素对肠道病毒感染心脏的影响
- 批准号:
8997975 - 财政年份:2015
- 资助金额:
$ 41.47万 - 项目类别:
Analyzing the effects of type I interferons in the enterovirus-infected heart
分析 I 型干扰素对肠道病毒感染心脏的影响
- 批准号:
9198190 - 财政年份:2015
- 资助金额:
$ 41.47万 - 项目类别:
Coxsackieviral pancreatitis: autophagy, proteolysis, and inflammation
柯萨奇病毒性胰腺炎:自噬、蛋白水解和炎症
- 批准号:
9027796 - 财政年份:2015
- 资助金额:
$ 41.47万 - 项目类别:
Coxsackieviral pancreatitis: autophagy, proteolysis, and inflammation
柯萨奇病毒性胰腺炎:自噬、蛋白水解和炎症
- 批准号:
8795589 - 财政年份:2015
- 资助金额:
$ 41.47万 - 项目类别:
mRNA as a mediator of immunological information transfer in vivo
mRNA 作为体内免疫信息传递的介质
- 批准号:
8735569 - 财政年份:2014
- 资助金额:
$ 41.47万 - 项目类别:
mRNA as a mediator of immunological information transfer in vivo
mRNA 作为体内免疫信息传递的介质
- 批准号:
8854024 - 财政年份:2014
- 资助金额:
$ 41.47万 - 项目类别:
mRNA as a mediator of immunological information transfer in vivo
mRNA 作为体内免疫信息传递的介质
- 批准号:
8894191 - 财政年份:2014
- 资助金额:
$ 41.47万 - 项目类别:
How do enteroviruses almost completely evade the attentions of CD8+ T cells?
肠道病毒是如何几乎完全逃避CD8 T细胞的注意的?
- 批准号:
8630094 - 财政年份:2014
- 资助金额:
$ 41.47万 - 项目类别:
相似国自然基金
P29单克隆抗体的3-羟基丁酰化修饰对其稳定性影响及提升抗泡型包虫病作用的研究
- 批准号:82360402
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
- 批准号:82304205
- 批准年份:2023
- 资助金额:20 万元
- 项目类别:青年科学基金项目
SARS-CoV-2 S2蛋白与肠道菌群交叉反应抗体的产生机制及其对新冠肺炎病程和疫苗效果的影响
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
模式识别受体通过调节脂质代谢影响中性粒细胞程序性死亡参与抗中性粒细胞胞浆抗体相关小血管炎发病机制的研究
- 批准号:
- 批准年份:2022
- 资助金额:53 万元
- 项目类别:面上项目
肠道菌群影响PD-1抗体对潜伏HIV的作用及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
IL-17A mRNA-targeted oligonucleotide therapeutics in Idiopathic Pulmonary Fibrosis (IPF)
IL-17A mRNA 靶向寡核苷酸治疗特发性肺纤维化 (IPF)
- 批准号:
10761365 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
Determining pathogenic PrPC-induced signaling pathways in human iPSC-induced neurons
确定人 iPSC 诱导神经元中致病性 PrPC 诱导的信号通路
- 批准号:
10791127 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies
抑制 IgE 的小檗碱纳米药物治疗食物过敏
- 批准号:
10698900 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别:
An immunotherapeutic IgY formulation against norovirus diarrhea
一种针对诺如病毒腹泻的免疫治疗 IgY 制剂
- 批准号:
10693530 - 财政年份:2023
- 资助金额:
$ 41.47万 - 项目类别: